Back to Search
Start Over
Guillain–Barré syndrome and its treatment
- Source :
- Expert Review of Neurotherapeutics. 6:1569-1574
- Publication Year :
- 2006
- Publisher :
- Informa UK Limited, 2006.
-
Abstract
- Guillain-Barré syndrome typically presents with an acute ascending areflexic weakness, progressing over 4 weeks or less. The most common form of the disease is an acute inflammatory demyelinating polyneuropathy, but other forms with primarily axonal pathologies are well documented. The association of Guillain-Barré syndrome with a range of antecedent infections, particularly Campylobacter jejuni enteritis, is also established. A range of serological and neurophysiological investigations can assist in making an accurate diagnosis. Background information about the syndrome and the evidence base for such treatments are discussed herein.
- Subjects :
- Background information
Weakness
Pediatrics
medicine.medical_specialty
biology
Guillain-Barre syndrome
business.industry
General Neuroscience
Disease
Guillain-Barre Syndrome
medicine.disease
biology.organism_classification
Campylobacter jejuni
Enteritis
Serology
Immunology
medicine
biology.protein
Humans
Pharmacology (medical)
Neurology (clinical)
medicine.symptom
business
Antiganglioside antibodies
Subjects
Details
- ISSN :
- 17448360 and 14737175
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- Expert Review of Neurotherapeutics
- Accession number :
- edsair.doi.dedup.....90617a1d71351c18b37ba4ec930acb06
- Full Text :
- https://doi.org/10.1586/14737175.6.10.1569